Molina Healthcare

Supporting Youth Behavioral Health a Top Priority for Molina Healthcare of Nevada

Retrieved on: 
torsdag, maj 30, 2024
Philanthropy, Mental Health, Health, Consumer, Telemedicine, Virtual Medicine, Teens, Other Philanthropy, Health care, Hope, Molina Healthcare, Depression, Male, Mental, Mental Health Awareness Month, Student, Suicide, Nursing

Molina Healthcare of Nevada (“Molina”) recently donated $50,000 to NAMI Western Nevada at NAMI’s 7th Annual Unmasked Gala in Carson City in honor of Mental Health Awareness Month.

Key Points: 
  • Molina Healthcare of Nevada (“Molina”) recently donated $50,000 to NAMI Western Nevada at NAMI’s 7th Annual Unmasked Gala in Carson City in honor of Mental Health Awareness Month.
  • The funds will be used to expand NAMI’s Nevada Teen Peer Support Text Line , a resource for individuals 24 years of age and younger who need non-crisis mental health supports.
  • “Many youth do not know where they would go for support if they did not have the Nevada Teen Peer Support Text Line."
  • “Anxiety, depression and feelings of inadequacy impact too many young people in our communities,” said Dr. Nima Alinejad, chief medical officer for Molina Healthcare of Nevada.

Nova Scotia Women's Centre Set To Expand Program to Prevent Youth Gender-Based Violence with $2.5M Boost

Retrieved on: 
måndag, maj 27, 2024
Pillar, MLA, Learning, Education, Dive (Belgian band), Justice, Molina Healthcare, Government, Public Health Agency, HRY, Participation, Safety, Religion, Norm (mathematics), Conseil scolaire acadien provincial, Report, Gender identity, Empathy, School, PHAC, Student, Curriculum, Communication, Policy, Knowledge, GBV, Violence, Advisory Council, Social, Nursing

The transformative HRY program helps shape society by creating safety through learning and building community and empowering youth as agents of change through the peer facilitation model.

Key Points: 
  • The transformative HRY program helps shape society by creating safety through learning and building community and empowering youth as agents of change through the peer facilitation model.
  • The program's effectiveness has also been recognized by the Nova Scotia Child and Youth Strategy, the Nova Scotia Department of Justice, and the Canadian Centre for Policy Alternatives.
  • HRY's curriculum design directly addresses topics recommended by the Report such as "prevent[ing] violence in the moment and address[ing] social and cultural factors that contribute to condoning gender-based violence.
  • Nova Scotia schools with grade nine to 12 students can participate in HRY by contacting Sarah Thomas at [email protected] .

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

Retrieved on: 
onsdag, maj 22, 2024
ATP, ACL, Risk, Molina Healthcare, Ageing, Agent handling, Adverse event, CVD, Esperion Therapeutics, Back pain, Angioedema, Cholesterol, Gout, Kidney, Constipation, Treatment, Civil service commission, European Commission, Fetus, Anaphylaxis, Hypersensitivity, Moyamoya disease, Bempedoic acid, Urinary tract infection, Anemia, Hypercholesterolemia, Upper respiratory tract infection, Safety, Ezetimibe, CLEAR, Incidence, Bronchitis, Excipient, Diet, Gallstone, Rash, Patient, Cardiovascular disease, Diarrhea, Abdominal pain, Uric acid, Spasm, University, University of Milan, Therapy, Arthralgia, Sinusitis, Pregnancy, European, Stroke, Health, Common, Death, FDC, Fatigue, Myocardial infarction, Tablet, Rupture, Pain, CHMP, Dietary supplement

ANN ARBOR, Mich. and MUNICH, Germany, May 22, 2024 (GLOBE NEWSWIRE) -- Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) and Esperion Therapeutics, Inc. jointly announced today that the European Commission (EC) has approved the label update of both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination (FDC)), as treatments for hypercholesterolemia (high levels of cholesterol) and to reduce the risk of adverse cardiovascular events. The EC’s decisions to update the labels of bempedoic acid and bempedoic acid / ezetimibe FDC are based on the positive CLEAR Outcomes trial results and makes them the first and only LDL-C lowering treatments indicated for primary and secondary prevention of cardiovascular events.

Key Points: 
  • Bempedoic acid is a first-in-class oral treatment which lowers cholesterol, and which can be combined with other treatments to help lower cholesterol even further.
  • Bempedoic acid provided additional cholesterol lowering of up to 28% on top of statin therapy, compared to placebo.
  • “Today's announcement marks a pivotal moment in our ongoing efforts to reduce cardiovascular risk.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Park National Corporation welcomes Kelly Gratz and Karen Morrison to Board of Directors

Retrieved on: 
tisdag, maj 21, 2024
Aircraft, University college, Health care, Greif, Public health, HBA, Health, Trustee, Industry Dive, Park National Bank, University, Government, OhioHealth, Health equity, Vanderbilt University, Molina Healthcare, Capital University, Gender, Knowledge, National Association, Management

NEWARK, Ohio, May 21, 2024 (GLOBE NEWSWIRE) -- Park National Corporation’s (NYSE American: PRK) (Park) board of directors announced today that they elected Karen Morrison and Kelly Gratz to serve as directors effective July 1, 2024.

Key Points: 
  • NEWARK, Ohio, May 21, 2024 (GLOBE NEWSWIRE) -- Park National Corporation’s (NYSE American: PRK) (Park) board of directors announced today that they elected Karen Morrison and Kelly Gratz to serve as directors effective July 1, 2024.
  • Both will also join the board of directors of The Park National Bank, Park’s banking subsidiary, effective on the same date.
  • “Karen and Kelly bring wisdom and a variety of experiences to Park,” said Park Chair and Chief Executive Officer David Trautman.
  • “I am thrilled to join Park’s board of directors, it is a profound honor,” said Gratz.

Study Shows High Volume Exercise Unrelated to Progression of Coronary Artery Calcium

Retrieved on: 
onsdag, maj 15, 2024
Moyamoya disease, Patient, Doctor of Philosophy, Athlete, News, Tyler, CCLS, University, Risk, Exercise, FACC, FAHA, FACP, CAC, Research, Atherosclerosis, University of Alabama, FACSM, Molina Healthcare, Cooper Union, Journal, Woman, Internal medicine, Environmental medicine, Knowledge, Behavioural sciences, CT scan, Cooper, Senior counsel

This new study , published in the Journal of the American Medical Association Cardiology, shows that the progression of CAC over time is not associated with leisure-time aerobic physical activity measured at baseline and follow-up.

Key Points: 
  • This new study , published in the Journal of the American Medical Association Cardiology, shows that the progression of CAC over time is not associated with leisure-time aerobic physical activity measured at baseline and follow-up.
  • Their physical activity, CAC and other clinical measurements were determined during preventive medicine visits to Cooper Clinic in Dallas, Texas.
  • Analysis of the data, which accounted for potential confounding factors, revealed that aerobic physical activity does not appear to elevate the rate of CAC progression.
  • “This study provides important new knowledge which will greatly assist in the care of Masters athletes and highly active people who have high coronary calcium scores.

Enhabit Provides Additional Details on Robust Strategic Review Process

Retrieved on: 
torsdag, maj 23, 2024
Seniors, Nursing, Managed Care, General Health, Health, Family, Consumer, Other Health, Medicare Advantage, CMS, Goldman Sachs, Form 10-K, UnitedHealth Group, Molina Healthcare, Average revenue per user, Letter, Centene Corporation, Encompass, Sale, AREX, CVS Health, Growth, File, Elevance Health, Transition, Environment, Annual general meeting, Pharmaceutical industry

In connection with the filing, Enhabit provided additional information regarding its recently concluded strategic review process.

Key Points: 
  • In connection with the filing, Enhabit provided additional information regarding its recently concluded strategic review process.
  • The Board, which includes two directors appointed as part of a cooperation agreement with Cruiser Capital and Harbour Point Capital, was actively engaged throughout the strategic review process.
  • In addition, Enhabit issued a public announcement of the process to ensure that other potential counterparties would be aware of the process.
  • The strategic review process, as described above, was publicly announced, comprehensive, and deliberate, lasting nine months and involving 38 potential counterparties.

Molina Healthcare of Wisconsin Receives Notice of Intent to Award New Region 5 Contract

Retrieved on: 
onsdag, maj 22, 2024
Health, Professional Services, Insurance, Managed Care, Health Insurance, Molina Healthcare, Health care, DHS

Molina Healthcare, Inc. (NYSE: MOH) announced today that the Wisconsin Department of Health Services (DHS) intends to make an award for the purchase of services in its Geographic Service Region 5 to Molina Healthcare of Wisconsin.

Key Points: 
  • Molina Healthcare, Inc. (NYSE: MOH) announced today that the Wisconsin Department of Health Services (DHS) intends to make an award for the purchase of services in its Geographic Service Region 5 to Molina Healthcare of Wisconsin.
  • The go-live date is expected to be January 1, 2025, and the contract is expected to have a duration of two years, with an option for three, two-year extensions.
  • Molina Healthcare of Wisconsin will offer the program benefits under the brand name, My Choice Wisconsin, and currently serves approximately 5,600 members in both the Family Care and Family Care Partnership program.
  • Wisconsin currently has approximately 55,000 total members enrolled in the Family Care and Family Care Partnership program.

First-in-class cholesterol-lowering treatment NILEMDO®▼ and its combination with ezetimibe, NUSTENDI®▼, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk

Retrieved on: 
onsdag, maj 22, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Moyamoya disease, Bempedoic acid, Patient, Cardiovascular disease, ATP, ACL, Risk, Molina Healthcare, University, Hypercholesterolemia, University of Milan, Therapy, Ageing, European, Agent handling, Ezetimibe, Civil service commission, European Commission, Death, Esperion Therapeutics, FDC, Cholesterol, CHMP, Dietary supplement

With the new indication, which covers both primary and secondary prevention, we can support healthcare professionals to better meet the treatment needs in their daily practice.

Key Points: 
  • With the new indication, which covers both primary and secondary prevention, we can support healthcare professionals to better meet the treatment needs in their daily practice.
  • At the same time, we’re confident it will reassure patients that their medication truly addresses their CV risk.
  • This reaffirms our commitment to be a trusted ally in improving cardiovascular care throughout Europe,” said Oliver Appelhans, Head of Europe Specialty Division, Daiichi Sankyo Europe GmbH.
  • “We are delighted with the European Commission’s approval, which reflects the significant cardiovascular risk reduction benefit that the bempedoic acid global franchise brings to patients worldwide,” said Sheldon Koenig, President and CEO, Esperion.

Vinmec's Innovations Spotlighted at Global CSR & ESG Summit 2024

Retrieved on: 
onsdag, maj 8, 2024
Education, Spectrum, Cleveland Clinic, Workplace, Vaccine, Culture, Patient safety, Accreditation, Medicine, JCI, Caesars Entertainment, Knowledge, AstraZeneca, Technology transfer, Haematopoietic system, CSR, Professional, Ageing, Molina Healthcare, COE, Hospital, GE HealthCare, Heart, PDSA, Research, Accountability, 3D, OMICS Publishing Group, CARE, Family, Immunology, Health, Ethics, Center of excellence, Organization, Platinum, Joint Commission, Empowerment, Interview, American College, Creativity, Leukemia, Environment, Patient, ESG, Cerebral palsy, COVID-19, Growth, Nursing

HANOI, Vietnam, May 9, 2024 - (ACN Newswire) - The 16th Annual Global CSR & ESG Summit & Awards 2024 was held on April 25 in Hanoi, Vietnam.

Key Points: 
  • HANOI, Vietnam, May 9, 2024 - (ACN Newswire) - The 16th Annual Global CSR & ESG Summit & Awards 2024 was held on April 25 in Hanoi, Vietnam.
  • The event showcased tremarkable strides in corporate social responsibility (CSR) and environmental, social, and governance (ESG) initiatives, and featured some of the most outstanding achievements by enterprises and organizations in this regard.
  • ACN: Can you share with us the vision and mission of Vinmec, particularly its dedication to academic healthcare for people at local and global scales?
  • Our emphasis on cutting-edgeinnovative applications like 3D printing and robotic surgery ensures clinical excellence and value-based solutions for our patients.

Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Retrieved on: 
torsdag, maj 9, 2024
Volunteering, FDA, Modulation, Ulcerative colitis, Solipsism syndrome, CDAI, Food, Risk, Molina Healthcare, NLRP3, Research and development, CAPS, Plasma, Webcast, Science, Administration, TYK2, IBD, Obesity, Week, SAD, European Medicines Agency, Patient, Treatment, Peripheral, EMA, Inflammation, CSF, Cardiovascular disease, Biomarker, MACE, G&A, SAN, UC, Pharmaceutical industry

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent pipeline and business progress.

Key Points: 
  • ET to discuss its first quarter 2024 financial results and provide a corporate update.
  • First Quarter 2024 Financial Results:
    Cash Position: Cash, cash equivalents and marketable securities were $302.6 million as of March 31, 2024.
  • Research and Development (R&D) expenses: R&D expenses were $33.7 million for the first quarter of 2024, compared to $35.4 million for the first quarter of 2023.
  • Net loss: Net loss was $38.6 million for the first quarter of 2024, compared to $38.9 million for the first quarter of 2023.